- Andrew Cittadine
CEO, American BioOptics
PROPEL is a group of programs aimed at increasing the number and success rates of life sciences startups in Illinois. Industry initially led the development of PROPEL through generous support from Abbott/AbbVie, Astellas Pharma US, Inc., Baxter International Inc. and Takeda Pharmaceuticals North America. Today, PROPEL has strong support from the broad life sciences community encompassing the three pillars of financial support: corporate/industry; private foundations; and public/government. In the last several years, funding sources include: iBIO, corporate partners (listed above), grants from the Searle Funds of The Chicago Community Trust, the City of Chicago and Illinois DCEO.
PROPEL helps guide the development of formation-stage and early-stage life sciences companies by providing entrepreneurs with access to specialized resources and expertise to prepare them for early-stage funding. Industry, academia, service professionals, entrepreneurs and government agencies connect to create and support a vibrant entrepreneurial community in Illinois and throughout the Midwest through PROPEL programs.
PROPEL programs include:
- Business Plan Presentation Panels
- Professional Services
- Technical Assistance
- Educational Programs and Networking
- PROPEL SBIR/STTR Awards and Other Grants and Awards Programs
- Chicago Innovation Mentors
- PROPEL Connections
- Business Plan Competition
Past and current PROPEL participants include:
- Formation-stage and early-stage companies
- Industry segments within therapeutics, medical devices, diagnostics, other healthcare-related products with intellectual property, biochemicals, industrial biotech products and agricultural-biotech products and processes